Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $32.0800 (-3.81%) ($31.5800 - $33.7900) on Thu. Dec. 14, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.51% (three month average) | RSI | 47 | Latest Price | $32.0800(-3.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -2.1% a day on average for past five trading days. | Weekly Trend | ADMS declines -0.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(27%) IBB(24%) IWM(19%) IWO(19%) QQQ(19%) | Factors Impacting ADMS price | ADMS will decline at least -2.255% in a week (0% probabilities). VIXM(-13%) BNDX(-9%) UUP(-8%) UNG(-7%) TLT(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.255% (StdDev 4.51%) | Hourly BBV | 0 () | Intraday Trend | -4% | | | |
|
Resistance Level | $33.65 | 5 Day Moving Average | $34.51(-7.04%) | 10 Day Moving Average | $34.71(-7.58%) | 20 Day Moving Average | $33.65(-4.67%) | To recent high | -13.6% | To recent low | 76.9% | Market Cap | $907m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |